Novartis’ kidney disease drug Fabhalta receives US FDA approval
Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.